CRB Inverb

CRB Inverbio continue to explore new investments opportunities and nurtures a live deal flow and investments opportunities with high potential

• Led by a senior and experienced team with sound track record in identifying science and technology of excellence and translating it into market opportunities and a large network and access to high potential deal flow
• Investment model includes hands on approach and access to a broad network of expertise: SAB, venture partners, portfolio CEOs, KOLs and best in class local and global partners
• CRB Inverbio has forged agreements with the top scientific biomedical research organisations and Life Science accelerators in Spain
• With more than €50M under management, CRB Inverbio portfolio includes some of the most promising healthcare technology based companies in Spain
• CRB Funds fill a gap in the market and contribute to accelerate industry and sector development
• CRB Inverbio SGEIC, SA is registered at the Spanish Securities and Exchange Commission (CNMV)
• Originated in a Research Institution with links to the National Health System
• Disruptive solution to an unmet global clinical need
• Global scope, big markets and existence of potential customers and partners
• Solid IP Protection and “freedom to operate”
• POC/Clinical evidence · Clear Regulatory pathway
• Experienced promotors and management team
• Clear space for divestment opportunities – high return opportunities